Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal

[ad_1] Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a quarterly loss,…

Merck & Co to buy immunology specialist Prometheus

[ad_1] Merck & Co has agreed to buy Prometheus Biosciences, which specialises in developing treatments for immune-modulated diseases, for $10.8 billion (£8.7 billion) in cash. The main focus of the…

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. – Merck.com

[ad_1] April 16, 2023 6:00 am ET PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target…

WSJ News Exclusive | Merck in Late-Stage Talks to Acquire Prometheus Biosciences

[ad_1] Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune…